IN-NTT/NTT-DATA
23.5.2024 16:06:30 CEST | Business Wire | Press release
NTT, a leading global technology and business solutions provider, and NTT DATA continue to expand innovative use of racing data to improve fan experiences across the NTT INDYCAR SERIES, including this year’s Indianapolis 500.
NTT is the parent company of NTT DATA, and they serve together as Official Technology Partner of INDYCAR, the NTT INDYCAR SERIES, Indianapolis Motor Speedway (IMS), the Indianapolis 500, and NASCAR Brickyard weekend.
Through 140-plus sensors on each racecar, NTT DATA captures and analyzes more than 8 billion racing datapoints in the NTT Smart Solutions Platform. Leveraging advanced AI and predictive analytics, the company shares near-real-time insights and visualizations to fans both onsite and remotely for enhanced storytelling of key moments during events including head-to-head overtaking, race strategies, race winner predictions and more. Additionally, the 300,000-plus fans onsite for the race benefit from data on wait times and flow across the 600-plus acre venue calibrated every 30 seconds.
SMART Venues Improve the Fan Experience
Fans at the Indianapolis 500 or other events at the Indianapolis Motor Speedway can experience NTT DATA Smart Venue technology, sustainability solutions and live race data at the Pagoda command displays. For example, AI-enabled optical detection technologies improve security and traffic flow, and when combined with digital ticketing, provide real-time and future prediction wait times at the event gates and concessions. This allows fans at the world’s largest single-day sporting event to move through the venue as safely and efficiently as possible.
AI-enabled Racing Insights
Whether at the racetrack, at home or on the go, fans of the NTT INDYCAR SERIES can also tap into the INDYCAR App Powered by NTT DATA to stay up to date on all of the latest developments. The App allows fans to get even closer to the action with real-time, AI and advanced analytics providing racing insights that include live scoring and viewing of the drivers in action courtesy of 15 in-car cameras. The App, which historically engages more than 70,000 users on race days, is available for download from the iOS App Store and Google Play.
NTT DATA also continues to enable other similar innovative experiences to benefit fans and increase engagement across all mediums, via social media, the web and television or streaming broadcast, through reliable technology and services that deliver deeper data insights.
Race Like the Pros
This year, a new limited racing demonstration will leverage Embodied Knowledge technology from NTT R&D. Embodied Knowledge powers simulators that blend physical sensations with digital innovation, allowing users to precisely experience a track as driven by a professional driver. Beyond the experience of traditional simulators, Embodied Knowledge adds the actual feel and performance of the professional driver at high speeds at the Indianapolis Motor Speedway including realistic steering wheel forces and car behavior like vibrations and forces exerted on seat, users can synchronize their movements with that of a professional driver via XR.
NTT Embodied Knowledge technology is being explored for future use cases including medical surgery training, coaching and fan experiences in sports. Future applications include employee training across retail, education, and manufacturing, as well as enabling AI-robots to learn how to move and react the way humans do to perform tasks from restocking shelves to in-home caregiving. The effort is part of the more than $3.6B NTT invests each year in research and development, uncovering innovations that have commercial impact for their customers.
“The Indianapolis 500 is the pinnacle of racing that leverages refined Embodied Knowledge where firsthand the movements of racers can be felt to understand what Embodied Knowledge truly means. Through various sensing technologies, we aim to technically recreate these movements and sensations.” said Kota Hidaka, Vice President, Head of NTT Human Informatics Laboratories.
To learn more about the NTT INDYCAR SERIES, visit: https://us.nttdata.com/en/about-us/content/ntt-indycar-series.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523988191/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom